Literature DB >> 24737608

State of the science in cervical cancer: where we are today and where we need to go.

Don S Dizon1, Helen J Mackay, Gillian M Thomas, Theresa L Werner, Elise C Kohn, Dina Hess, Peter G Rose, Allan L Covens.   

Abstract

Invasive cervical cancer remains an important global cause of death, despite the declining prevalence within the United States. Definitive therapies, including surgical resection of early-stage disease and chemoradiation for locally advanced disease, can be curative. For women who experience local or distant recurrences, the prognosis remains poor and better treatments are required. On July 18, 2013, The Gynecologic Oncology Group sponsored a State of the Science in Cervical Cancer Symposium with experts, researchers, clinicians, and interested stakeholders. This article summarize the progress that has been made, questions that require further investigation, and contemporary genomic findings and innovative treatments that may help inform the next generation of clinical trials for patients with cervical cancer.
© 2014 American Cancer Society.

Entities:  

Keywords:  anti-angiogenesis; cervical cancer; clinical trials; human papillomavirus; immunotherapy; prevention; screening

Mesh:

Year:  2014        PMID: 24737608     DOI: 10.1002/cncr.28722

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

1.  PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.

Authors:  Hong-Yun Zheng; Fu-Jin Shen; Yong-Qing Tong; Yan Li
Journal:  Curr Med Sci       Date:  2018-03-15

2.  MicroRNA-195 inhibits proliferation of cervical cancer cells by targeting cyclin D1a.

Authors:  Ning Wang; Heng Wei; Duo Yin; Yanming Lu; Yao Zhang; Qiao Zhang; Xiaoxin Ma; Shulan Zhang
Journal:  Tumour Biol       Date:  2015-10-28

3.  Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond.

Authors:  Helen J Mackay; Lari Wenzel; Linda Mileshkin
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

4.  Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240).

Authors:  Krishnansu S Tewari; Michael W Sill; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Philip J DiSaia; Larry J Copeland; William T Creasman; Frederick B Stehman; Mark F Brady; Robert A Burger; J Tate Thigpen; Michael J Birrer; Steven E Waggoner; David H Moore; Katherine Y Look; Wui-Jin Koh; Bradley J Monk
Journal:  Lancet       Date:  2017-07-27       Impact factor: 79.321

5.  Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline.

Authors:  H Hirte; E B Kennedy; L Elit; M Fung Kee Fung
Journal:  Curr Oncol       Date:  2015-06       Impact factor: 3.677

6.  Down-regulated Circ_0000190 promotes cervical cancer by facilitating the activity of proto-oncogene protein EIF4E.

Authors:  Chengcheng Yang; Jia Xie; Qian Chen; Yisi Yang
Journal:  Cell Cycle       Date:  2022-04-13       Impact factor: 5.173

7.  Cervical cancer treated with reduced-volume intensity-modulated radiation therapy base on Sedlis criteria (NCCN VS RTOG).

Authors:  Hua-Chun Luo; Gui-Shan Lin; Shao-Guang Liao; Feng-Mei Wang; Hui-Hua Cheng; Jing Feng; Qin Yin; Qun-Hua Chen; Jin-Feng Zhu; Jian-Feng Xu; Dian Wang; Zhi-Chao Fu
Journal:  Br J Radiol       Date:  2017-12-05       Impact factor: 3.039

8.  Retracted Article: Down-regulation of the radiation-induced pEGFRThr654 mediated activation of DNA-PK by Cetuximab in cervical cancer cells.

Authors:  Yunxiang Qi; Jinyi Lang; Xiaodong Zhu; Jianming Huang; Lu Li; Guangming Yi
Journal:  RSC Adv       Date:  2020-01-06       Impact factor: 3.361

Review 9.  Challenges in Prevention and Care Delivery for Women with Cervical Cancer in Sub-Saharan Africa.

Authors:  Thomas C Randall; Rahel Ghebre
Journal:  Front Oncol       Date:  2016-06-28       Impact factor: 6.244

10.  E3 ubiquitin ligase isolated by differential display regulates cervical cancer growth in vitro and in vivo via microRNA-143.

Authors:  Jibin Li; Xinling Wang; Yanshang Zhang; Yan Zhang
Journal:  Exp Ther Med       Date:  2016-06-06       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.